Role of the renin-angiotensin-aldosterone system in dystrophin-deficient cardiomyopathy

Moises Rodriguez-Gonzalez1,*, Manuel Lubian-Gutierrez2,3, Helena Maria Cascales-Poyatos4, Alvaro Antonio Perez-Reviriego4 and Ana Castellano-Martinez2,6

1 Pediatric Cardiology Division of Puerta del Mar University Hospital, Cadiz, Spain.
2 Pediatric Neurology Division of Puerta del Mar University Hospital, Cadiz, Spain.
3 Pediatric Division of Doctor Cayetano Roldan Primary Care Center, San Fernando, Spain.
4 Pediatric Division of Motril-San Antonio Primary Care Center, Motril, Spain.
5 Pediatric Nephrology Division of Puerta del Mar University Hospital, Cadiz, Spain.
6 Biomedical Research and Innovation Institute of Cadiz (INiBICA), Research Unit, Puerta del Mar University Hospital. University of Cadiz, Cadiz, Spain.
* Correspondence: doctormoisesrodriguez@gmail.com; Tel.: +34 956002700
Received: date; Accepted: date; Published: date

Abstract: Dystrophin-deficient cardiomyopathy (DDC) is currently the leading cause of death in patients with dystrophinopathies. Targeting myocardial fibrosis (MF) has become a major therapeutic goal in order to prevent the occurrence of DDC. We aimed to review and summarize the current evidence about the role of the renin-angiotensin-aldosterone system (RAAS) in the development and perpetuation of MF in DDC. We conducted a comprehensive search of peer-reviewed English literature on PubMed about this subject. We found increasing preclinical evidence from studies in animal models during the last 20 years pointing out a central role of RAAS in the development of MF in DDC. Local tissue RAAS acts directly mainly through its main fibrotic component angiotensin II (ANG2) and its transducer receptor (AT1R) and downstream TGF-b pathway. Also, it modulates the actions of most of the remaining pro-fibrotic factors involved in DDC. Despite limited clinical evidence, RAAS blockade constitutes the most studied, available and promising therapeutic strategy against MF and DDC. Conclusion: Based on the evidence reviewed, it would be recommendable to start RAAS blockade therapy through angiotensin converter enzyme inhibitors (ACEI) or AT1R blockers (ARBs) alone or in combination with mineralocorticoid receptor antagonists (MRA) at the youngest age after the diagnosis of dystrophinopathies, in order to delay the occurrence or slow the progression of MF, even before the detection of any cardiovascular alteration.

Keywords: Dystrophinopathy; Duchenne muscular disease; Becker muscular disease; Dystrophic deficient cardiomyopathy; Cardiac fibrosis; Renin angiotensin system; Angiotensin 2; Angiotensin converter enzyme inhibitors; Angiotensin receptor blockers.

1. Introduction

Dystrophinopathies are heterogeneous X-linked recessive disorders with a common genetic origin, mutations in the dystrophin gene (DMD OMIM300377; chromosome Xp21.1.) that lead to the complete loss or deficient synthesis of the dystrophin protein. Dystrophinopathies include a broad genetic and phenotypic spectrum, mainly Duchenne muscular disease (DMD), the most common and severe form, and Becker muscular dystrophy (BMD) [1, 2]. The varying degree of dystrophin expression explains the different clinical courses of these diseases: while DMD results from a complete loss of dystrophin, BMD is due to the expression of a truncated but partially functional protein (Table 1). The absence of dystrophin protein in the heart results in these patients invariably developing dystrophin-deficient cardiomyopathy (DDC), mainly in the form of dilated cardiomyopathy (DCM) with congestive heart failure (CHF) and rhythm disturbances [3].
A clinically evident cardiac involvement has been reported in 25% of patients under the age of 6 years, increasing to 60% of patients between the ages of 6-10 years [3], and is present in virtually all patients with DMD over 18 years of age. DDC is currently the leading cause of premature death in both entities and reducing its occurrence has become a major therapeutic for dystrophinopathies [4].

Dystrophin is a large (427 kDa) protein normally found at the cytoplasmic surface of the sarcolemma, where is crucial to maintain the structural integrity of membrane of skeletal and cardiac muscle cells by connecting the subsarcolemmal cytoskeleton to the extracellular matrix through the dystrophin-associated protein complex and laminin. This complex forms a mechanically strong link that stabilize the sarcolemma against cycles of intracytoplasmic contractions and relaxations of muscular cells, thereby acting like a shock absorber and protecting muscle fibres from their inherent associated biomechanical stress [5, 6]. Dystrophin acts also as a pivotal regulator of important intracellular processes either directly by regulating membrane-associated proteins, including ion channels [7], or indirectly via calcium (Ca2+) [8], nitric oxide (NO) [9], and reactive oxygen species (ROS) [4] second messenger cascades.

The absence or the presence of a deficient dystrophin protein alters the normal interaction and signal transduction between the cytoskeleton and the extracellular matrix in the cardiomyocyte [6]. The increased vulnerability of the cardiomyocyte sarcolemma to the stretch-induced injury generates physical sarcolemmal micro-tears during muscle contraction and sarcolemmal stretch-activated ion channels dysregulation [10-13]. These primary events favour an excessive influx of extracellular Ca2+ into the cell with cytosolic Ca2+ overload [4, 8], leading to widespread effects on intracellular signalling and metabolic pathways [4, 14, 15], including activation of calcium dependent proteases [16-19], activation of nuclear factor kappa B (NF-κB), dysregulation of nitric oxide synthase (NOS) with altered nitric oxide (NO) production [4, 20-23], and mitochondrial dysfunction with increased reactive oxygen species (ROS) production [4, 24-28]. These processes finally culminate in myocyte cell death, necrosis, inflammation, and replacement of contractile myocardium by fibrotic tissue, the histopathological hallmark of DDC [4, 29-32]. The loss of viable myocardium leads to a rise in wall stress and after load excess within healthy myocardium, favouring further losses of a vulnerable dystrophin-deficient myocardium and activation of local and circulating renin angiotensin aldosterone system (RAAS)[33]. Increasing evidence points out the key role of the renin-angiotensin-aldosterone system (RAAS), and its major effectors angiotensin II (ANG2) and aldosterone in the development and perpetuation of MF and DCC [36-38]. Thus, the inhibition of RAAS has emerged one of the main therapeutic targets recommended for the management of DCC.

In this article, we aim to review the current evidence about the participation of RAAS in the genesis and progression of myocardial fibrosis (MF) in DDC. We also will summarize the preclinical and clinical results of pharmacologic RAAS blockade, highlighting the relevance to target RAAS to prevent, delay or ameliorate the subsequent adverse myocardial remodelling in this setting.
Figure 1. Schematic representation integrating the main pathophysiological mechanisms involved in the cellular damage, cell death and subsequent inflammatory response, fibrosis and RAAS activation in dystrophic deficient cardiomyopathy. 1) Loss of membrane integrity, that causes a calcium leak to cytosol by passive influx, action of ion channels (TRP/LTCC) or release of calcium from SR. 2) Activation of proteases; with degradation of intracellular proteins; 3) Dysregulated nNOS expression and increase of iNOS expression; 4) Mitochondrial dysfunction and increased activity of NOX2 with production of ROS. These products cause mitochondrial damage and cell death. 6) Probable impaired microvasculature with recurrent ischemia may be one of the causes of cardiac muscle cell, apoptosis and fibrosis.[34, 35] 7) Activation of local and circulating RAAS after accumulating cardiomyocyte necrosis occurs, perpetuating the fibrotic process. Abbreviations: ACE: angiotensin-converting enzyme; iNOS: inducible nitric oxide synthase; LTCC: L-type Ca2+ channels; nNOS: neuronal nitric oxide synthase; NOX2: NADPH oxidase 2; RAAS: renin-angiotensin-aldosterone system; ROS: reactive oxygen species; TRP: transient receptor potential; RyR2: Ryanodine receptor 2; SERCA2: Sarcoplasmic/endoplasmic reticulum calcium ATP-ase.
2. Literature review and results

We conducted a comprehensive search of peer-reviewed literature on PubMed in order to identify evidence about the role of the RAAS in DDC. We used the following search terms: ‘Duchenne muscular dystrophy’, ‘Becker muscular dystrophy’, ‘dystrophic cardiomyopathy’, ‘dystrophin deficient cardiomyopathy’, ‘renin-angiotensin system’, ‘angiotensin receptor’, ‘cardiac fibrosis’, ‘myocardial fibrosis’, ‘angiotensin converter enzyme inhibitors’, ‘angiotensin receptor blockers. Reference lists of the articles identified by this strategy were also searched. Inclusion of articles was based on relevance to the topic, quality of the manuscript and consistency with the literature. Only articles published in English were included in this review. With this search we identified relevant articles about the activation and physiopathological actions of RAAS in dystrophic cardiomyocytes, about preclinical investigations of RAAS blockade on MF in animal dystrophic models, and about clinical evidence of RAAS blockade in humans, that will be summarized in the discussion section.

3. Discussion

The development of MF is the cornerstone pathophysiological mechanism in DDC. The development of new imaging techniques such as cardiac MRI with LGE has led to an increased identification of the presence of MF in children, a population where myocardial biopsies are not usually performed [39, 40]. Noteworthy, cardiac MRI is usually performed at the age when sedation is not necessary and LGE technique requires a minimum threshold volume of myocardial fibrosis before becoming evident on CMR. Consequently, this can lead to a delayed identification or underestimation of MF. The detection of early subclinical cardiovascular manifestations long before the identification of MF on cardiac MRI points out that MF could be present already at early stages of the disease [41], and this period would be a large window of opportunity for interventions aimed at preventing MF occurrence [31, 32, 42]. The understanding of the pathophysiological processes leading to the development of MF in DDC is crucial for this purpose. During the last 20 years a growing knowledge has been obtained from parallel investigation in animal models and humans suggesting that RAAS is a pivotal pathway in the regulation of MF in DDC. RAAS blockade has become the hallmark of cardioprotective interventions to ameliorate the adverse myocardial remodelling and progression of heart failure that follows cardiomyocyte necrosis in dystrophinopathies [43]. Indeed, current guidelines recommend that children with DMD should start on RAAS inhibition (including AT1R blockers (ARBs), and ACEI) by age 10 or earlier if myocardial dysfunction is detected [44].

3.1. Overview of the fibrotic process in DDC

After the occurrence of cardiac injury and cardiomyocyte death secondary to absent or defective dystrophin protein, the inflammatory/immune cells (lymphocytes, macrophages, mast cells) infiltrate the wounded myocardium to clear dead tissue and release pro-fibrotic cytokines. This led to differentiation of cardiac fibroblasts into myofibroblasts, the major effectors for the pathological MF and remodelling observed in DDC [45-49]. The repetitive chronic injurious stimuli that occur in dystrophinopathies may cause perpetual activation of myofibroblasts leading to excessive deposits of extracellular matrix (ECM) materials, progressive fibrosis and maladaptive cardiac remodelling. Major characteristics of muscle biopsies of the dystrophic hearts include necrotic muscle fibres surrounded by macrophages, lymphocytes, mast cells and myofibroblasts [31, 42, 50, 51], supporting that DDC results from imbalance between muscle fibre necrosis, inflammatory response and myofibroblasts regeneration [30, 52-58]. At the molecular level, the fibrotic process is regulated by a complex network of signalling pathways that includes inflammatory cells (lymphocytes, macrophages, mast cells), inflammatory factors (IL, TNF-a, NF-kB),...), peptides (ANG2, endothelin 1 (ET-1), aldosterone), growth factors (Transforming growth factor (TGF-β), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF)), ions (Ca2+), oxidative stress molecules (NADPH, NOX, LOX...), adhesion molecules (integrins, osteopontin), matrix metalloproteinases (MMP), and immunoproteasome (Figure 2) [59-65]. These interdependent factors favour the activation and proliferation of myofibroblasts [66-68]. The increased mechanical tension of the
myocardium due to the changes in ECM stiffness also acts as alternative regulator of myofibroblasts differentiation. The histopathologic findings of a greater degree of fibrotic changes in basal cardiac region than the apical region of dystrophic hearts, reinforce that mechanical forces influences in the development of MF in DDC [45, 47, 69-75].

All the mentioned above mechanisms involved in MF in DDC are similar to those occurring in more studied models, such as myocardial infarct or hypertension, where the RAAS has been extensively shown to modulate the actions of most of the remaining pro-fibrotic and pro-inflammatory factors mentioned above, mainly through its primary effector molecule ANG2 and the ANG2 type 1 receptor (AT1R) [76-81].

3.2. Evidence about sources, activation and actions of RAAS in DDC

3.2.1. Circulating RAAS

In the dystrophic myocardium the progressive fibrotic replacement led to loss of myocardial contractility and relaxation with decreased cardiac output and increased vulnerability to pressure or volume overloading conditions. This provokes the chronic activation of circulating RAAS in the kidney, resulting in increased pressure and volume overload for the damaged myocardium, which serves as substrate for a positive feed-back to perpetuate the increased plasmatic ANG2 concentrations observed in these patients [52]. The major counter regulatory hemodynamic effects of ANG2 include vasoconstriction, intravascular fluid retention, and increased heart rate and cardiac contractility. ANG2 also stimulates the production and release of aldosterone from the adrenal cortex. Together, the resulting endocrine effects of ANG2 and aldosterone on their target organs serve to maintain blood pressure and restore renal perfusion [82, 83].

Cardiac dysfunction with activated circulating RAAS is mostly developed in the later stage of DDC, when echocardiographic alterations such as dilated cardiomyopathy or myocardial dysfunction are evident [84]. Interestingly, the intramuscular RAAS is activated in dystrophic human skeletal muscles, [77] and could be an important source of circulating ANG2 at early stages of dystrophinopathies in absence of evident myocardial dysfunction or cardiac overload conditions [85]. Circulating ANG2 seems to be a relevant modulator of the autonomic heart function in DDC. The AT1R are present on cardiac sympathetic nerve terminals, and the ANG2/AT1R binding provokes norepinephrine (NE) exocytosis and release from the adrenal medulla and sympathetic nerve endings by stimulating the neuronal Na+/H+ exchanger [86, 87]. It has been shown that autonomic dysfunction caused by activation of RAAS and manifested as reduced heart rate variability or inappropriate sinus tachycardia, is present at early stages of the disease and worsens progressively with age. Of note, the precocity and severity of this autonomic dysfunction predicts the severity of DDC at older ages and ANG2/AT1R blockade reduces oxidative stress and fibrosis and improved improves autonomic function and cardiac functionality in dystrophic mice [88-90].

3.2.2. Local cardiac RAAS.

Accumulating evidence supports the central role of a local cardiac RAAS mediating the adverse myocardial remodelling process in DDC. The local synthesis of RAAS components was documented in dystrophic hearts in animal models by Nakamura et al. in 2001. They demonstrated that the RNA expression of ANG2 and AT1R was increased in mdx mice as compared to those in wild type mice [91]. This over-expression of ACE and AT1 in dystrophic hearts would likely result in the local increased production of ANG2 which may act on these cells in an autocrine manner via AT1R. There are important and bidirectional local interactions between aldosterone and ANG2 within the myocardium, which potentiate the persistent activity of RAAS in DDC [64, 82, 92-98]. The pharmacologic RAAS blockade has shown to decrease the inflammatory infiltrate and fibrotic changes in hearts of dystrophic mdx mice models, reinforcing the major regulatory role of ANG2/Aldosterone in the myocardial fibrotic network in DDC [54, 99-103].
Figure 2. Schematic representation of the complex network of interplayed cellular and molecular mechanisms that participle in the development of myocardial fibrosis leading to the occurrence of dystrophin-deficient cardiomyopathy. Notice that angiotensin 2 with its type 1 receptor, have a central role modulating the activation of most of these pathways through its autocrine/paracrine actions, mostly via the TFG-β pathway. Angiotensin 2 is also essential in order to maintain and perpetuate the profibrotic response, providing a source for a positive auto-feedback. Abbreviations: ACE: angiotensin-converting-enzyme; Akt: protein kinase B; ALK5: activin receptor-like kinase-1; Ang I: angiotensin I; Ang II: angiotensin II; CCN2/CTGF: connective tissue growth factor; ET1: endothelin-1; ETA: endothelin receptor A; JNK: Jun N-Terminal Kinase; LAP: latency-associated peptides; MMPs: matrix metalloproteinases; NADH: reduced nicotinamide adenine dinucleotide; PDGF: platelet derived growth factor; PI3: phosphoinositide 3; ROS: reactive oxygen species; Smad3/4: mothers against decapentaplegic homolog ¾; TFG-β: transforming growth factor-beta; TNF-α: tumor necrosis factor alpha; α-SMA: alpha-smooth muscle actin; βFGF: basic fibroblast growth factor.
ANG2 mediates the fibrogenic response via ATIR binding (Figure 3) directly with the subsequent activation of mainly ERK1/2, JNK, and p38MAPK intracellular signalling networks; and indirectly via induction of TGF-β1/SMAD pathway expression and NF-kB pathway activation. Finally, these downstream cascades result in the release of pro-inflammatory cytokines (TNF-alfa, interleukins), the expression of growth factors (CTGF), angiogenic factors (PDGF), ROS molecules generation and the upregulation of synthesis of proteins involved in modulating myofibroblast collagen synthesis [54, 61, 72, 73, 104-119].

The p38-MAPK and ERK 1/2 signalling pathways have been shown to be activated in dko and mdx mice hearts, supporting their participation in MF in DDC. [55, 75, 91, 120]. TGF-β1 appears to be the most important mediator of myofibroblast activation and ECM protein synthesis at the damaged myocardium in DDC (Figure 3) [121-127]. The promotion of MF fibrosis via the TGF-β1 signalling pathway has been widely documented during the last 20 years in mdx hearts. Overexpression of TGF-β signalling pathways in dystrophic hearts correlates with the grade of myocardial fibrosis and cardiac dysfunction in DDC [128-135]. Recent investigations in mdx mice models showed that TGF-β antagonism with halofuginone and reduction of TGF-β expression through gene therapy prevented the development of MF [136, 137]. Remarkably, ATIR blockade with losartan in mdx mice has been shown to be associated with a dramatic decrease in fibrotic cardiac area and lower levels of serum TFG-b, supporting the direct role of ANG2/TGF-β complex in the development of DDC [54, 138]. CTGF is another key mediator of early and persistent MF in DDC models [128]. The up-regulation of CTGF by ANG2 and TGF-β and their relationship with MF has been widely described in myocardium in both DMD patients and mdx mice models [128, 130, 139, 140]. Of note, the onset of cardiac fibrosis is associated with increased CTGF transcript and protein expression, and the high levels of TGF-β1 and CTGF are associated with increased histopathologic findings of MF. Furthermore, the use of ARBs and mineralocorticoid receptor antagonists (MRAs) minimizes the expression of CTGF and the induced MF in dystrophic mice models [121, 130]. ANG2/TGF-β axis is also known to transactivate the PDGF receptor (PDGFR). The PDGF family is reported to mediate MF in patients with DMD and blocking PDGFs can reduce fibrosis the mdx mouse model [129, 141]. The accumulation of ECM components in fibrosis can result not only from increased expression of matrix components, but also from the decreased degradation of the ECM. The primary enzymes responsible for ECM degradation are the MMPs which are blocked by the TIMPs. Importantly TIMP’s expression is downstream of TGF-β and CTGF signalling. Recent studies demonstrated increase levels of MMPs in DMD humans and in mdx mice models, where they were correlated with the level of TGF-β. ANG2 is involved in pressure overload-induced cardiac fibrosis mediated by MMPs [128, 133, 142-144]. Osteopontin is an adhesion molecule that promotes cardiac fibrosis by enhancing macrophage activation and fibroblast proliferation stimulated by ANG2 and aldosterone [145]. Reactive oxygen species and activation of members of the MAPK super family would mediate this effect. In mdx mice models, osteopontin contributes to the increased amounts of MMPs, MF and myocardial dysfunction [146-148].

Oxidative stress and inflammatory pathways are relevant and interrelated second messengers modulating the profibrotic actions of RAAS in the MF process in dystrophin deficient hearts. ANG2 requires oxidative stress generation in dystrophic myocytes to induce most of its pro-fibrotic (TGF-β/CTFG and ERK1/2 pathways) and pro-inflammatory (NF-kB pathway) effects [149-152]. The ANG2/aldosterone binding with ATIR and MR induces cardiac tissue remodelling and dysfunction in DCC mediated by ROS production via the nicotinamide adenine dinucleotide phosphate (NADPH) and the Nox family proteins, particularly Nox4 [153-158]. There are multiple reports of excessive NADPH oxidase-mediated ROS production contributing to skeletal injury in mdx mice, and early and chronic RAAS blockade has shown to protect against fibrosis and inflammation reducing the production of ROS and the activation of NF-kB pathways [108]. Although there is no direct evidence about RAAS blockade benefits on cardiac tissue remodelling, AT1R inhibition may benefit DMD patients by limiting the amplification of myocardial injury secondary to excessive ROS production in the dystrophic heart.
Figure 3. Integrated schematic representation of the local RAAS (classical (ACE/Angiotensin 2/ATR) and counterregulatory non-classical (ACE2/Angiotensin1-7/Mas-r), with its main pro-fibrotic intracellular mechanisms, and its relevant interactions with the profibrotic TGF-β pathway. TGF-β transduce its signal from the membrane to the nucleus through its receptors (TGF-βR) and their main downstream effectors, the regulatory SMAD proteins (canonical pathways). [126]. The activation of alternative SMAD-independent signalling cascades (non-canonical pathways) by TGF-β, including the ERK, JNK, and p38MAPKs, is also required for myofibroblasts pro-fibrotic actions enhancing transcription of pro-fibrotic signals, including TGF-β itself, as part of the positive feedback in fibrosis [127]. Abbreviations: ACE: angiotensin-convertingenzyme; ALK5: activin receptor-like kinase-1; AT1R: angiotensin II receptor type 1; AT2R: angiotensin II receptor type 2; ERK: extracellular signal-regulated kinase; FAK: focal adhesion kinase; JNK: Jun N-Terminal Kinase; MAPK: mitogen-activated protein kinase; MasR: Mas receptor; MEK: MAPK/ERK kinase SMAD: mothers against decapentaplegic homolog; TAK1: tumor growth factor β-activating kinase-1; TGF-βR: transforming growth factor-β receptor.
ANG2 and aldosterone promote cardiac inflammatory response mainly activating the NF-κB pro-inflammatory pathway. Increased NF-κB pro-inflammatory factors are associated with MF and myocardial dysfunction on echocardiography, and blunting NF-κB signalling in dko and mdx mice reduces inflammatory markers, enhances myofiber regeneration, and improves cardiac contractile dysfunction [92, 159, 160]. Furthermore, inflammatory cells produce pro-inflammatory factors, such as tumour necrosis factor alpha (TNF-α), that further contribute to muscle degeneration and substitution of muscle fibers by fibrosis. TNF-α blocking correlated with reductions in MF in mdx models [131, 161-164]. ANG2 also induces TNF-α expression, facilitating cardiac interstitial and perivascular fibrosis through increased collagen, CTGF, and TGF-β production. In dystrophin-deficient hearts, this response is dependent on TNF-α-induced ROS production and downstream activation of NF-κB, p38MAPK, and JNK. Furthermore, TNF-α exacerbates the ANG2 response through feedback regulation of AT1R [55, 165]. Finally, the immunoproteasome has been reported to play an important role in controlling immune responses, oxidative stress, and maintaining cellular protein homeostasis. Generation and activation of the immunoproteasome is implicated in ANG2-induced cardiac fibrosis. Interestingly, its dysregulation has been observed in dystrophic hearts of mdx mice, and its inhibition ameliorated cardiomyopathy and reduced the development of cardiac fibrosis in this setting [166, 167].

The evidence summarized above point out that ANG2 could be implicated in a wide variety of cellular and molecular pro-fibrotic pathways in the DDC setting, and therefore, the RAAS blockade could act as a promising antifibrotic therapeutic strategy to prevent MF in dystrophinopathies.

3.3. Evidence about the effects of the RAAS blockade on MF in dystrophic-deficient cardiomyopathy

3.3.1. Preclinical evidence from mice models

Over the past 15 years, several preclinical studies performed with dystrophic murine models have provided strong evidence about the beneficial effects of medications blocking RAAS actions on DDC. Specifically, blocking ACE/AT1R/MR treatment with ACEi (enalapril/lisinopril), ARBs (losartan) and MRa (spironolactone/eplerenone) respectively, has been shown to prevent the occurrence, slow the progression or decrease the extension of MF, and also to improve cardiac functionality without significant side effects. This reinforces the involvement and the role of RAAS as a key regulator of MF in DDC. Here we briefly detail the results of most relevant preclinical studies.

3.3.1.1. Single therapy with ACEi

Bauer et al. [101] investigated the effects of steroids and ACEi on development of left ventricular dysfunction in the mdx mouse, a model for DDC. They found that untreated and prednisolone mdx mice groups showed reduced myocardial contractility, ventricular dilatation, diastolic dysfunction and patchy myocardial fibrosis but preserved stroke volume. Of note, the administration of ACEi (captopril) during 8 weeks in mdx mice was associated with improved cardiac function and decreased after load. Blain et al. [168] designed a comparative study between single versus combined treatment with ACEi (captopril) and beta-blockers in mdx models. They reported that ACEi therapy at early stages of DDC improved stroke volume and cardiac output, and reduced maximum systolic pressures, with no effect on right ventricular function. They also observed a reduced heart to body weight ratios. These findings support beneficial hemodynamic effects of ACEi to reduce or delay the occurrence of DDC.

3.3.1.2. Single therapy with ARBs

Spurney et al. [54] assessed cardiac function via in vivo high frequency echocardiography in mdx mice and found that chronic treatment with losartan for 6 months lead to a significant improvement of cardiac function, reduction cardiac after load, and of note to a significant reduction of MF compared to untreated mdx mice. Bish et al. [103] evaluated the cardiac effects of chronic
losartan administration in mdx mice with existing DDC. In the treated group they observed a significantly preserved cardiac function with decreased areas of MF after 2 years of treatment. They also found a 2-fold higher survival associated with losartan therapy (88% vs 44%). These results point out that ARB may be an important prophylactic strategy for slow the progression of DDC. Lee et al. [138, 169] examined the safety of chronic ARBs therapy. Through histopathological findings and serum biochemistry analyses, they observed that losartan inhibits MF and prevented muscular degeneration with no significant effects on other organs after 44 weeks of treatment. Besides inhibiting MF, losartan also showed important beneficial and protective cardiovascular and metabolic effects, being associated with decreased LDH, AST, BUN and triglyceride levels and increased high-density lipoprotein (HDL) levels. Sabharwal et al. [88-90] provided interesting evidence when studied the effects of ARBs on the autonomic dysregulation casted by ANG2 in dystrophic Sgcd−/− mice. They found that early autonomic dysfunction precedes and predicts the severity of LV dysfunction and mortality. Of note, treatment with losartan at a young age was associated with improved autonomic function, reduced oxidative stress, and fibrosis, with subsequent delay in the occurrence of DDC and improved survival. These findings have relevant implications. As the early occurrence of subclinical signs of dysautonomia (inappropriate sinus tachycardia, low heart rate variability…) is well-known in DMD patients, the initiation of treatment with losartan at this time and not waiting to the detection of echocardiographic findings could improve the survival of these patients. Recently, Meyers et al. [170] provided relevant evidence about the preventive role of losartan in MF. They administered isoproterenol (10 mg/kg) to induce cardiac stress and injury in mdx and wild type (C57Bl/10) mice. They found that the administration of losartan previous to induce cardiac damage was significantly associated with a reduction in the area of MF of mdx mice. They also observed a reduction of the initial inflammatory response to injury. These findings strongly suggest that earlier adoption of angiotensin receptor blockers in DMD patients could limit MF and subsequent DDC with improvement of the cardiovascular and metabolic profile.

3.3.1.3. Single therapy with MRa

Lowe et al. [99] used the MRa finerenone in monotherapy in preclinical dystrophic mice model. They observed that treatment with finerenone alone was associated with improvement in functional cardiac parameters, with significant reductions in myocardial strain rate, the earliest echocardiographic sign of DDC. As finerenone is more selective (non-steroidal) MRa compared with eplerenone and spironolactone, this study highlights the chronic use of finerenone without side-effects of steroidal MRa. Heier et al. [171] investigated the effects of vamorolone, a dissociative glucocorticoid receptor ligand with anti-inflammatory efficacy, on dystrophin-deficient hearts using mdx mouse models. They showed that vamorolone is effective as MRa to prevent MF without side effects, and that these antifibrotic effects are due to its combined anti-inflammatory and MRa properties. The results of both authors point out a possible role for MRa in mono therapy in these patients. However, testing this scenario is challenging due to the extended clinical practice to use MRa always in combination with ACEI or ARBs in the setting of pediatric heart failure.

3.3.1.4. Combined ACEI/ARBs plus MRa therapy

Rafael-Fortney et al. [102] investigated the use of the combination lisinopril plus spironolactone on the development of DDC in mdx mice. They found that the group that received this regimen presented a 44% of reduction in MF and a further 53% reduction when the treatment started at early stages of the disease. Also, they observed the cardiac function decreased 50% slower in the treated mice. Therefore, combining MRas with ACEI at an extremely early stage potentially offers superior outcomes in patients with DDC. Lowe et al. [172] observed similar efficacy using two different MRas, spironolactone and eplerenone, in combination with ACEI (lisinopril). Both therapeutic regimens lead to cardiac functional and histopathological improvements with significant side effects. Lowe et al. [173] also compared histopathologic findings of DDC in 3 groups of mice model (mdx sedentary,
mdx exercised and mdx injured by isoproterenol) treated with the combination ACEI/MRA and they did not find any benefit in any model. The authors suggested the relevance of early initiation of combined ACEI/MRA treatment to prevent DDC development because the beneficial effects of these drugs are likely to occur only during the initial inflammatory phase after the myocardial injury. The authors also suggest that continuous use of these drugs could be ineffective based on the absence of prolific damage and inflammation in exercised and aged mdx mice. Janssen et al. [174] studied the added value of the combinations lisinopril/spironolactone and losartan/spironolactone versus corticosteroid therapy alone in mdx mice at early stages of the disease. All treatments were initiated at 4 weeks-of-age, and physiological and histological end-point assessments evaluated at 20 weeks-of-age. They observed an improvement in the phenotype of contractile dysfunction and MF that was not different when comparing ACEI/MRA and ARB/MRA groups. Interestingly, treated and steroid treatment groups presented increased MF and decreased myocardial function when assessed by cardiac MRI. These results suggest the early use of combined treatments blocking RAAS to prevent DDC. Interestingly, ACEI and ARBs are reported to block CTGF and TFG-β expression respectively in skeletal muscle of mdx mice [175]. These results suggest that both drugs could be complementary as they act blocking different pathways involved in MF. Therefore, they would be used in combination at early stages of the disease to prevent the occurrence of MF.

3.3.1.5. Limitations to translate preclinical results to the clinical practice in DDC

The results of most preclinical studies regarding the efficacy and safety of RAAS blockade to prevent MF in DDC are excellent. Until recently, the only possibility to model DDC was to use animal models, overall mice models that do not accurately recapitulate the human disease course (Table 2). Mice cardiomyocytes differ from human cells in the expression of key contractile proteins, heart rate, electrical properties and ion channel function, often making it challenging to translate results to humans and clinical practice. Notably, the most used mice model (mdx) in preclinical studies of DDC, is characterized by a milder cardiac and skeletal muscle phenotype than humans with no premature death. Several variants of this model have been developed during years, but no one resembles well the dystrophic phenotype of humans [53, 176-185]. Dystrophic canine models present many similarities to humans, making them an interesting model to use in preclinical therapeutic studies. Also, the assessment of heart failure and cardiac function is easy in dogs compared with mice. However, there is also some divergence between affected dogs and humans, such as higher mortality rates at birth, ambulation maintained in young affected dogs, disease progression stabilizing at 6–10 months, and observations of increased phenotype divergence. The lower availability and higher times to achieve results and costs compared with mice models are also important limitations [186].

**Table 2.** Mouse models used in the study of dystrophinopathies and heart phenotype.

| Genotype   | Life expectancy | DDC age of onset | Histopathology | Echocardiographic changes |
|------------|-----------------|-----------------|----------------|--------------------------|
| Wild tipe  | 2 years         | None            | Normal         | None                     |
| mdx        | 1.5–2 years     | 10 months       | Mild           | Mild/none                |
| mdx/Utr    | 20 weeks        | 8 weeks         | Moderate       | Moderate                 |
| mdx/Dtna   | 8-10 months     | 4 weeks         | Moderate/severe| -                        |
| mdx/7      | <4 weeks        | 3 weeks (20 days)| Mild          | None                     |
| mdx/Myod1  | 12 months       | 5 months        | Severe         | -                        |
| mdx/Cmah   | 11 months       | 3 months        | Moderate/severe| -                        |
| mdx/mTR G2 | 4-12 months     | 32 weeks        | Severe         | Severe                   |

Adapted from Yucel et al [187]. Abbreviations: DDC: dystrophin-deficient cardiomyopathy.

In the light of these limitations, recent advances in DDC modelling highlight the most remarkable findings obtained from cardiomyocytes derived from patients DMD induced pluripotent
stem cells (iPSCs). The discovery of these cells has led to create in vitro DDC models mimicking the histological, molecular and clinical characteristics observed in the human disease. Thus, iPSCs offer an accurate tool to study human DDC progression and screening or develop potential therapeutic approaches [188-190].

3.3.2. Clinical evidence from human studies

The efficacy and safety of therapeutic strategies targeting RAAS have been also evaluated in human studies in parallel with those preclinical studies mentioned above. Pharmacological approaches used include similar drugs (ACEI, ARBs and MRa) used in dystrophic mice. The marked benefits of these therapeutic regimens improving the outcomes of several cardiovascular disorders with associated MF (heart failure, hypertension, myocardial infarction, congenital heart disease) without relevant side effects, and the positive preclinical effects shown, have led to the use of these drugs in daily clinical practice in patients with dystrophinopathies. Notably, beta-blockade per se could reduce fibrosis and could be one mechanism of action of RAAS inhibition in reducing MF. However, the specific contribution of beta-blockers could not be clearly separated from RAAS inhibition intervention on myocardial fibrosis reduction as they are usually used in combination. In the last 15 years several studies suggest that the RAAS blockade has the capacity to limit the accumulation of fibrosis, delay the occurrence and slow the progression of DDC in humans. However, most of the supporting has been gathered from retrospective non-randomized studies (Table 3). A recent Cochrane review [191] updated in 2017 including five randomised controlled trials (RCTs) with 205 patients with dystrophinopathies (DMD and BMD) concluded that early treatment with ACE inhibitors or ARBs may be comparably beneficial, and that adding eplerenone might give additional benefit when early cardiomyopathy is detected. However, the quality of evidence resulted very low due to the small size and other limitations of the studies. Remarkably, the trials provided only low or very low-certainty evidence on side effects.

4. Conclusions

The present review has focused on the activation of cardiac RAAS following myocardial damage in dystrophinopathies and the regulatory role of ANG2 on cardiac repair/remodelling associated with the occurrence of DDC. The field of investigation about potential curative treatments for dystrophinopathies has evolved considerably in recent years, leading to multiple therapeutic strategies including gene therapy (exon skipping, micro-dystrophins, etc.) for restoration of dystrophin expression or increase the expression of utrophin protein, and treatments blocking the different pathophysiological mechanisms associated with the absence of dystrophin (oxidative stress, calcium homeostasis, NF-kB pathway, mitochondria dysfunction, etc). There are currently more than 200 clinical trials ongoing in DMD patients with promising results. However, most studies focus on the impact of such treatments on skeletal muscle function not in DDC. MF is an early and otherwise unavoidable event that determines the occurrence of DDC in patients with dystrophinopathies, which should be evaluated promptly because it carries fatal consequences. RAAS, in particular the ANG2/AT1IR complex, plays a crucial role in the development of MF by means of both, direct profibrotic actions and also modulating different inflammatory cells and profibrotic pathways, mainly TFG-β. Most of these actions can be interrupted blocking the AT1R and therefore, RAAS antagonists (ACEI, ARBs and MRa alone or in combination) represent a promising approach for the management of DDC. Extensive preclinical investigations have consistently demonstrated the potential of RAAS antagonists to prevent the occurrence and slow the progression of MF and DDC, showing improved survival and lack of relevant side effects in dystrophic mice models. The results of clinical studies in humans correlates with those in animal models, reinforcing the potential benefit and safety of these therapies. Nevertheless, the level of clinical evidence is still very low and on the short term, and there are important issues that difficult the translation of preclinical results to patients.
Table 3. Summary of the different investigations in humans about the inhibition of the RAAS and DDC outcomes.

| Author               | Type of study                      | Size       | Interventions                                                                 | Outcomes                                                                                       |
|----------------------|------------------------------------|------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Hor et al. (2011)    | Retrospective cohort study         | DMD: 136   | Deflazacort or prednisone and lisinopril or enalapril or losartan; Glucocorticoid alone: 114 | ACE-I/ARB therapy combined with glucocorticoids did not arrest the decline in cardiac function. |
| Raman et al. (2019)  | Double-blind, randomized, noninferiority trial | DMD: 52    | Eplerenone: 26/52; Spironolactone: 26/52                                    | Spironolactone added to background therapy is noninferior to eplerenone in preserving heart function. |
| Raman et al. (2015)  | Randomized, double-blind, placebo-controlled trial | DMD: 42    | Eplerenone: 20/42; Placebo: 22/42                                            | Eplerenone added to ACEI or ARB therapy attenuates the progressive decline ventricular function. |
| Raman et al. (2017)  | Randomized, double-blind, placebo-controlled trial | DMD: 11    | Eplerenone; Placebo                                                           | Eplerenone is a useful if is initiated in the first phases with no relevant dysfunction.         |
| Duboc et al. (2007)  | Randomized Control Trial           | DMD: 57    | Phase I (3 years): 56/57 Perindopril or Placebo. - Phase II (2 years): 51/57 Perindopril | Phase I: improvement of ventricular function in 55/56 patients. Phase I and II: Early treatment with perindopril delayed the onset and progression of prominent left ventricle dysfunction. |
| Jefferies et al. (2005) | Retrospective case series.              | DMD: 62; BMD: 7 | ACE inhibitors: 13/31; ACE inhibitor and β-blocker: 18/31                       | 2/29: showed no deterioration in LV function. 8/29: showed improvement in LV size or function or both. 19/29: showed normalization of LV size or function or both. |
| Duboc et al. (2005)  | Randomized Control Trial           | DMD: 57    | Placebo: 29/57; Perindopril: 28/57                                          | Early initiation of treatment with perindopril is associated with a lower mortality in patients with DMD with normal LV ejection fraction at study entry. |
| Ramaciotti et al. (2006) | Retrospective case series.              | DMD: 50    | Enalapril                                                                      | 10/26 (43%) presented improvement with the use of enalapril normalizing the shortening fraction. |
| Kajimoto et al. (2006) | Randomized Control Trial           | DMD: 25; FMD: 2; EDM: 1 | Enalapril or Cilazapril and Carvedilol: 13/28 - ACE-I alone: 15/28          | No significant change was observed in patients who received ACE-I monotherapy. Carvedilol plus an ACEI improves left ventricular systolic function in patients with muscular dystrophy. |
| Ogata et al. (2009)  | Retrospective cohort study         | DMD: 52    | Enalapril or Lisinopril and Bisoprol or Metoprol or Cavedil                   | In DMD patients with heart failure the combination of an ACE inhibitor and a beta-blocker had a beneficial effect on survival. |
| Kwon et al. (2012)   | Retrospective cohort study         | DMD: 22; BMD: 1 | Enalapril 13/23; Carvedilol: 10/23                                          | Carvedilol or Enalapril could improve LV systolic function in patients with muscular dystrophy. |
| Viollet et al. (2012) | Retrospective cohort study         | DMD: 42    | Lisinopril and metoprolatenol: Lisinopril                                     | Treatment with ACE inhibitor or ACE inhibitor plus BB can delay progression of cardiomyopathy. |
| Allen et al. (2013)  | Randomized Control Trial           | DMD: 23    | Losartan: 11/23; Lisinopril: 12/23                                          | LV Ejection fraction improved equally with two difference therapeutic.                             |
| Silva et al. (2016)  | Randomized Control Trial           | DMD: 70; BMD: 6 | Placebo: 21/76; Enalapril: 21/76                                           | ACEI slows Myocardial fibrosis progression at a 2-year follow-up                                 |

DMD (Duchenne muscular dystrophy); BMD (Becker muscular dystrophy); ACEI (angiotensin-converting enzyme inhibitors); ARBs (angiotensin receptor blocker); LV: left ventricle; FMD (Fukuyama muscular dystrophy); EDM (Emery-Dreifuss muscular dystrophy).
Despite these limitations and until the future implementation of novel therapies under investigation mentioned above can be feasible, the RAAS blocking constitutes the more studied, available and promising therapeutic strategy against MF and DDC. Based on the evidence reviewed, it would be recommendable to start RAAS blockade therapy through ACEI or ARB in combination with MRa at the youngest age after the diagnosis of dystrophinopathies in order to delay the occurrence or slow the progression of MF, even before the detection of any cardiovascular alteration. Further investigations to expand the understanding of the pathophysiological mechanisms leading to MF are essential to improve intervention strategies for DDC.

**Author Contributions:** Conceptualization, Moises Rodriguez-Gonzalez; Data curation, Moises Rodriguez-Gonzalez, Helena Maria Cascales-Poyatos and Alvaro Antonio Perez-Reviriego; Formal analysis, Miriam Ley-Martos; Investigation, Moises Rodriguez-Gonzalez, Manuel Lubian-Lopez, Helena Maria Cascales-Poyatos, Alvaro Antonio Perez-Reviriego and Ana Castellano-Martinez; Methodology, Moises Rodriguez-Gonzalez; Resources, Miriam Ley-Martos; Software, Manuel Lubian-Lopez; Supervision, Manuel Lubian-Lopez and Miriam Ley-Martos; Writing – original draft, Moises Rodriguez-Gonzalez and Ana Castellano-Martinez; Writing – review & editing, Moises Rodriguez-Gonzalez, Manuel Lubian-Lopez, Helena Maria Cascales-Poyatos, Alvaro Antonio Perez-Reviriego, Miriam Ley-Martos and Ana Castellano-Martinez.

**Funding:** This research received no external funding

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations:**

ACE | Angiotensin-converting-enzyme
Akt | Protein kinase B
ALK5 | Activin receptor-like kinase-1
Ang I | Angiotensin I
ANG II | Angiotensin II
ARBs | AT1R blockers
AT1R | Angiotensin II receptor type 1
AT2R | Angiotensin II receptor type 2
BMD | Becker muscular dystrophy
CCN2/CTGF | connective tissue growth factor
CHF | Congestive heart failure
CF | Cardiac fibrosis
cTn | Cardiac troponin
DCM | Dilated cardiomyopathy
DDC | Dystrophin-deficient cardiomyopathy
DMD | Duchenne muscular dystrophy
ERK | Extracellular signal-regulated kinase
ET1 | Endothelin-1
ETA | Endothelin receptor A
FAK | Focal adhesion kinase
JNK | Jun N-Terminal Kinase
iNOS  Inducible nitric oxide synthase
LTCC  L-type Ca2+ channels
LVH   Left ventricular hypertrophy
LVSD  Left ventricular systolic dysfunction
LVDD  Left ventricular diastolic dysfunction
MAPK  Mitogen-activated protein kinase
MasR  Mas receptor
MEK   MAPK/ERK kinase
MF    Myocardial fibrosis
MMPs  Matrix metalloproteinases
MP    Myopericarditis
MRI   Magnetic resonance imaging
NADH  Reduced nicotinamide adenine dinucleotide
NF-κB Nuclear factor kappa B
nNOS  neuronal nitric oxide synthase
NOX2  NADPH oxidase 2
NP    Natriuretic peptides
PDGF  Platelet derived growth factor
PI3   Phosphoinositide 3
ROS   Reactive oxygen species
TAK1  Tumor growth factor β-activating kinase-1
TGF-β  Transforming growth factor-β
TGF-βR Transforming growth factor-β receptor
TIMPs Tissue inhibitors of metalloproteinases
TRP   Transient receptor potential
RyR2  Ryanodine receptor 2
SMAD Mothers against decapentaplegic homolog
SERCA2 Sarcoplasmic/endoplasmic reticulum calcium ATP-ase
TFG-β  Transforming growth factor-beta
TNF-α  Tumor necrosis factor alpha
VA    Ventricular arrhythmias
α-SMA Alpha-smooth muscle actin
βFGF basic fibroblast growth factor

References
1. Brandsema JF, Darras BT. Dystrophinopathies. Semin Neurol 2015; 35: 369-84.
2. Morales JA, Mahajan K. Dystrophinopathies. StatPearls. Treasure Island (FL) 2020.
3. Kamdar F, Garry DJ. Dystrophin-Deficient Cardiomyopathy. Journal of the American College of Cardiology 2016; 67: 2533-46.
4. Meyers TA, Townsend D. Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy. International journal of molecular sciences 2019; 20.
5. Gao QQ, McNally EM. The Dystrophin Complex: Structure, Function, and Implications for Therapy. Comprehensive Physiology 2015; 5: 1223-39.
6. Le S, Yu M, Hovan L et al. Dystrophin As a Molecular Shock Absorber. ACS nano 2018; 12: 12140-8.
7. Koenig X, Ebner J, Hilker K. Voltage-Dependent Sarcolemmal Ion Channel Abnormalities in the Dystrophin-Deficient Heart. International journal of molecular sciences 2018; 19.
8. Rubi L, Todt H, Kubista H et al. Calcium current properties in dystrophin-deficient ventricular cardiomyocytes from aged mdx mice. Physiological reports 2018; 6.
9. Hammers DW, Sleeper MM, Forbes SC et al. Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts. Journal of the American Heart Association 2016; 5.
10. Viola HM, Davies SM, Filipovska A, Hool LC. L-type Ca(2+) channel contributes to alterations in mitochondrial calcium handling in the mdx ventricular myocyte. American journal of physiology Heart and circulatory physiology 2013; 304: H767-75.
11. Johnstone VP, Viola HM, Hool LC. Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies. Genes 2017; 8.
12. Vandebrouck C, Martin D, Colson-Van Schoor M et al. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. The journal of cell biology 2002; 158: 1089-96.
13. Lorin C, Vogeli I, Niggl E. Dystrophic cardiomyopathy: role of TRPV2 channels in stretch-induced cell damage. Cardiovascular research 2015; 106: 153-62.
14. Whitehead NP, Yeung EW, Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clinical and experimental pharmacology & physiology 2006; 33: 657-62.
15. Vallejo-Illarramendi A, Toral-Ojeda I, Aldanondo G, Lopez de Munain A. Dysregulation of calcium homeostasis in muscular dystrophies. Expert reviews in molecular medicine 2014; 16: e16.
16. Turner PR, Westwood T, Regen CM, Steinhardt RA. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 1988; 335: 735-8.
17. Spencer MJ, Croall DE, Tidball JG. Calpains are activated in necrotic fibers from mdx dystrophic mice. The Journal of biological chemistry 1995; 270: 10909-14.
18. Badalamente MA, Stracher A. Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. Muscle & nerve 2000; 23: 106-11.
19. Loboda A, Dulak J. Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacological reports : PR 2020; 72: 1227-63.
20. Bia BL, Cassidy PJ, Young ME et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. Journal of molecular and cellular cardiology 1999; 31: 1857-62.
21. Sander M, Chavoshan B, Harris SA et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 13818-23.
22. Dombernowsky NW, Olmestig JNE, Witting N, Kruuse C. Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies - Still a possible treatment modality? Neuromuscular disorders : NMD 2018; 28: 914-26.
23. Balligand JL, Ungureanu-Longrois D, Simmons WW et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. The journal of biological chemistry 1994; 269: 27580-8.
24. Kryuchenko V, Polakova E, Janicek R, Shirokova N. Mitochondrial dysfunctions during progression of dystrophic cardiomyopathy. Cell calcium 2015; 58: 186-95.
25. Prosser BL, Ward CW, Lederer WJ. X-ROS signaling: rapid mechano-chemo transduction in heart. Science 2011; 333: 1440-5.
26. Allen DG, Whitehead NP, Froehner SC. Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. Physiological reviews 2016; 96: 253-305.
27. Katsetos CD, Koutzaki S, Melvin JJ. Mitochondrial dysfunction in neuromuscular disorders. Seminars in pediatric neurology 2013; 20: 202-15.
28. Buyse GM, Goemans N, van den Hauwe M et al. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuro muscular disorders : NMD 2011; 21: 396-405.

29. Shin J, Tajrishi MM, Ogura Y, Kumar A. Wasting mechanisms in muscular dystrophy. The international journal of biochemistry & cell biology 2013; 45: 2286-79.

30. Quinlan JG, Hahn HS, Wong BL et al. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuro muscular disorders : NMD 2004; 14: 49-16.

31. Finsterer J, Stollerberger C. The heart in human dystrophinopathies. Cardiology 2003; 99: 1-19.

32. Tandon A, Villa CR, Hor KN et al. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. Journal of the American Heart Association 2015; 4.

33. Adoriso R, Mencarelli E, Cantarutti N et al. Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies. Journal of clinical medicine 2020; 9.

34. Hor KN, Johnston P, Kinnett K et al. Progression of Duchenne Cardiomyopathy Presenting with Chest Pain and Troponin Elevation. Journal of neuromuscular diseases 2017; 4: 307-14.

35. Mendell JR, Engel WK, Derrer EC. Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science 1971; 172: 1143-5.

36. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circulation research 2010; 106: 1675-80.

37. Tarbit E, Singh I, Peart JN, Rose/Meyer RB. Biomarkers for the identification of cardiac fibroblast and myofibroblast cells. Heart failure reviews 2019; 24: 1-15.

38. Cao L, Chen Y, Lu L et al. Angiotensin II upregulates fibroblast-myofibroblast transition through Cx43-dependent CaMKII and TGF-beta1 signaling in neonatal rat cardiac fibroblasts. Acta biochimica et biophysica Sinica 2018; 50: 843-52.

39. Power LC, O’Grady GL, Hornung TS et al. Imaging the heart to detect cardiomyopathy in Duchenne muscular dystrophy: A review. Neuro muscular disorders : NMD 2018; 28: 717-30.

40. D’Amario D, Amodeo A, Adoriso R et al. A current approach to heart failure in Duchenne muscular dystrophy. Heart 2017; 103: 1770-9.

41. Mavrogeni SI, Markousis-Mavrogenis G, Papavasiiliou A et al. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies. Methods in molecular biology 2018; 1687: 31-42.

42. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. International journal of cardiology 1990; 26: 271-7.

43. McNally EM, Kallman JR, Benson DW et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation 2015; 131: 1590-8.

44. Birnkranz DJ, Bushby K, Bann CM et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. The Lancet Neurology 2018; 17: 347-61.

45. Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. Journal of molecular and cellular cardiology 2016; 97: 245-62.

46. Haudek SB, Cheng J, Du J et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. Journal of molecular and cellular cardiology 2010; 49: 499-507.

47. Leask A. Getting to the heart of the matter: new insights into cardiac fibrosis. Circulation research 2015; 116: 1269-76.

48. Crowley SD, Coffman TM. Recent advances involving the renin-angiotensin system. Experimental cell research 2012; 318: 1049-56.

49. Weber KT, Sun Y, Bhattacharya SK et al. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nature reviews Cardiology 2013; 10: 15-26.

50. Nishimura T, Yanagisawa A, Sakata H et al. Thallium-201 single photon emission computed tomography (SPECT) in patients with duchenne's progressive muscular dystrophy: a histopathologic correlation study. Japanese circulation journal 2001; 65: 99-105.

51. Sanyal SK, Johnson WW, Thagar MK, Pitner SE. An ultrastructural basis for electrocardiographic alterations associated with Duchenne’s progressive muscular dystrophy. Circulation 1978; 57: 1122-9.

52. Kamogawa Y, Biro S, Maeda M et al. Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo. Cardiovascular research 2001; 50: 509-15.

53. Lefaucheur JP, Sebille A. Basic fibroblast growth factor promotes in vivo muscle regeneration in murine muscular dystrophy. Neuroscience letters 1995; 202: 121-4.
54. Spurney CF, Sali A, Guerron AD et al. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. *Journal of cardiovascular pharmacology and therapeutics* 2011; **16**: 87-95.

55. Nakamura A, Yoshida K, Takeda S et al. Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice. *FEBS letters* 2002; **520**: 18-24.

56. Cohn RD, Durbeej M, Moore SA et al. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. *The Journal of clinical investigation* 2001; **107**: R1-7.

57. Marques MJ, Barbin IC, Taniguti AP et al. Myocardial fibrosis is unaltered by long-term administration of L-arginine in dystrophin deficient mdx mice: a histomorphometric analysis. *Acta biologica Hungarica* 2010; **61**: 168-74.

58. Fan D, Takawale A, Lee J, Cassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. *Fibrogenesis & tissue repair* 2012; **5**: 15.

59. Stempien-Otero A, Kim DH, Davis J. Molecular networks underlying myofibroblast fate and fibrosis. *Journal of molecular and cellular cardiology* 2016; **97**: 153-61.

60. Liu F, Liang Z, Xu J et al. Activation of the wnt/beta-Catenin Signaling Pathway in Polymyositis, Dermatomyositis and Duchenne Muscular Dystrophy. *Journal of clinical neurology* 2016; **12**: 351-60.

61. Davis J, Molkentin JD. Myofibroblasts: trust your heart and let fate decide. *Journal of molecular and cellular cardiology* 2014; **70**: 9-18.

62. Duerrschmidt C, Trial J, Wang Y et al. Tumor necrosis factor: a mechanistic link between angiotensin-II-induced cardiac inflammation and fibrosis. *Circulation Heart failure* 2015; **8**: 352-61.

63. Takawale A, Zhang P, Patel VB et al. Tissue Inhibitor of Matrix Metalloproteinase-1 Promotes Myocardial Fibrosis by Mediating CD63-Integrin beta1 Interaction. *Hypertension* 2017; **69**: 1092-103.

64. Ma F, Li Y, Jia L et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. *PloS one* 2012; **7**: e35144.

65. Wang X, Wang HX, Li YL et al. MicroRNA Let-7i negatively regulates cardiac inflammation and fibrosis. *Hypertension* 2015; **66**: 774-85.

66. Chen C, Du J, Feng W et al. beta-Adrenergic receptors stimulate interleukin-6 production through Epac-dependent activation of PKCdelta/p38 MAPK signalling in neonatal mouse cardiac fibroblasts. *British journal of pharmacology* 2012; **166**: 676-88.

67. Liu N, Xing R, Yang C et al. HIP-55/DBNL-dependent regulation of adrenergic receptor mediates the ERK1/2 proliferative pathway. *Molecular bioSystems* 2014; **10**: 1932-9.

68. Fu X, Khalil H, Kanisicak O et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. *The Journal of clinical investigation* 2018; **128**: 2127-43.

69. Schroer AK, Merryman WD. Mechanobiology of myofibroblast adhesion in fibrotic cardiac disease. *Journal of cell science* 2015; **128**: 1865-75.

70. Zhou Y, Huang X, Hecker L et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. *The Journal of clinical investigation* 2013; **123**: 1096-108.

71. Kural MH, Billiar KL. Myofibroblast persistence with real-time changes in boundary stiffness. *Acta biomaterialia* 2016; **32**: 223-30.

72. Li L, Fan D, Wang C et al. Angiotensin II increases peristin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-beta1 pathways in cardiac fibroblasts. *Cardiovascular research* 2011; **91**: 80-9.

73. Wu H, Chen L, Xie J et al. Peristin expression induced by oxidative stress contributes to myocardial fibrosis in a rat model of high salt-induced hypertension. *Molecular medicine reports* 2016; **14**: 774-82.

74. Kawano H, Cody R, Graf K et al. Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts. *Hypertension* 2000; **35**: 273-9.

75. Megeney LA, Kablar B, Perry RL et al. Severe cardiomyopathy in mice lacking dystrophin and MyoD. *Proceedings of the National Academy of Sciences of the United States of America* 1999; **96**: 220-5.

76. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. *Experimental physiology* 2008; **93**: 519-27.

77. Sun G, Haginoya K, Dai H et al. Intramuscular renin-angiotensin system is activated in human muscular dystrophy. *journal of the neurological sciences* 2009; **280**: 40-8.

78. Zamai L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. *Cells* 2020; **9**.

79. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signalling and function. *Clinical science* 2001; **100**: 481-92.

80. Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? *Circulation research* 1999; **85**: 643-50.
81. Bader M. Molecular interactions of vasoactive systems in cardiovascular damage. *Journal of cardiovascular pharmacology* 2001; **38 Suppl 2**: S7-9.

82. Catena C, Colussi G, Brosolo G et al. Aldosterone and Left Ventricular Remodeling. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme* 2015; **47**: 981-6.

83. Kamnik SS, Unal H, Kemp JR et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. *Pharmacological reviews* 2015; **67**: 754-819.

84. Sermeri GG, Boddi M, Cecioni I et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. *Circulation research* 2001; **88**: 961-8.

85. Danser AH, van Kats JP, Admiraal PJ et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. *Hypertension* 1994; **24**: 37-48.

86. Reid AC, Mackins CJ, Seyedi N et al. Coupling of angiotensin II AT1 receptors to neuronal NHE activity and carrier-mediated norepinephrine release in myocardial ischemia. *American journal of physiology Heart and circulatory physiology* 2004; **286**: H1448-54.

87. Seyedi N, Win T, Lander HM, Levi R. Bradykinin B2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings. Mediation by autocrine/paracrine mechanisms. *Circulation research* 1997; **81**: 774-84.

88. Sabharwal R, Chapleau MW. Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin system. *Experimental physiology* 2014; **99**: 627-31.

89. Sabharwal R, Weiss RM, Zimmerman K et al. Angiotensin-dependent autonomic dysregulation precedes dilated cardiomyopathy in a mouse model of muscular dystrophy. *Experimental physiology* 2015; **100**: 776-95.

90. Sabharwal R, Cicha MZ, Sinisterra RD et al. Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy. *Clinical science* 2014; **127**: 101-9.

91. Nakamura A, Harrod GV, Davies KE. Activation of calcineurin and stress activated protein kinase/p38 mitogen activated protein kinase in hearts of utrophin-dystrophin knockout mice. *Neuromuscular disorders : NMD* 2001; **11**: 251-9.

92. Nitahara-Kasahara Y, Hayashita-Kinoh H, Chiyto T et al. Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10. *Human molecular genetics* 2014; **23**: 3990-4000.

93. Wehling-Henricks M, Jordan MC, Gotoh T et al. Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy. *PloS one* 2010; **5**: e10763.

94. Johar S, Cave AC, Narayanapanicker A et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2006; **20**: 1546-8.

95. Hirono Y, Yoshimoto T, Suzuki N et al. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. *Endocrinology* 2007; **148**: 1688-96.

96. De Mello WC, Frohlich ED. Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems. *Frontiers in endocrinology* 2014; **5**: 16.

97. Uehara Y, Miura S, Yahiro E, Saku K. Non-ACE pathway-induced angiotensin II production. *Current pharmaceutical design* 2013; **19**: 3054-9.

98. Ferrario CM, Ahmad S, Varagic J et al. Intracellular angiotensin II functions originate from noncanonical pathways in the human heart. *American journal of physiology Heart and circulatory physiology* 2016; **311**: H404-14.

99. Lowe J, Kolkhof P, Haupt MJ et al. Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy. *ESC heart failure* 2020.

100. Meyers TA, Townsend D. Early right ventricular fibrosis and reduction in biventricular cardiac reserve in the dystrophin-deficient mdx heart. *American journal of physiology Heart and circulatory physiology* 2015; **308**: H1305-15.

101. Bauer R, Straub V, Blain A et al. Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. *European journal of heart failure* 2009; **11**: 463-71.

102. Rafael-Fortney JA, Chimani JS, Schill KE et al. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. *Circulation* 2011; **124**: 582-8.

103. Bish LT, Yarchoan M, Sleeper MM et al. Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. *PloS one* 2011; **6**: e20856.
104. Morales MG, Cabrera D, Cespedes C et al. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell and tissue research 2013; 353: 173-87.

105. Cabello-Verrugio C, Cordova G, Salas JD. Angiotensin II: role in skeletal muscle atrophy. Current protein & peptide science 2012; 13: 560-9.

106. Laurino A, Spinelli V, Gencarelli M et al. Angiotensin-II Drives Human Satellite Cells Toward Hypertrophy and Myofibroblast Trans-Differentiation by Two Independent Pathways. International journal of molecular sciences 2019; 20.

107. Cozzoli A, Nico B, Sblendorio VT et al. Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice. Pharmacological research 2011; 64: 482-92.

108. Peterson JM, Wang DJ, Shettigar V et al. NF-kappaB inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model. Nature communications 2018; 9: 3431.

109. Bondi CD, Manickam N, Lee DY et al. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. Journal of the American Society of Nephrology : JASN 2010; 21: 93-102.

110. Cleutjens JP, Verluyen MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. The American journal of pathology 1995; 147: 325-38.

111. Whittaker P, Kloner RA, Przyklenk K. Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine. Circulation 1996; 93: 2043-57.

112. Fomovsky GM, Rouillard AD, Holmes JW. Regional mechanics determine collagen fiber structure in healing myocardial infarcts. Journal of molecular and cellular cardiology 2012; 52: 1083-90.

113. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. American journal of physiology Cell physiology 2007; 292: C82-97.

114. Liu Q, Zhang Q, Wang K et al. Renal Derivation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy. Scientific reports 2015; 5: 18582.

115. Travers JG, Kamal FA, Robbins J et al. Cardiac Fibrosis: The Fibroblast Awakens. Circulation research 2016; 118: 1021-40.

116. Li C, Han R, Kang L et al. Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-alpha in myocardial infarction-induced cardiac fibrosis. Scientific reports 2017; 7: 40523.

117. Sano M, Fukuda K, Sato T et al. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circulation research 2003; 89: 661-9.

118. George M, Vijayakumar A, Dhanesh SB et al. Molecular basis and functional significance of Angiotensin II-induced increase in Discoidin Domain Receptor 2 gene expression in cardiac fibroblasts. Journal of molecular and cellular cardiology 2016; 90: 59-69.

119. Olson ER, Shamhart PE, Naugle JE, Meszaros JG. Angiotensin II-induced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase C delta and intracellular calcium in adult rat cardiac fibroblasts. Hypertension 2008; 51: 704-11.

120. Su X, Shen Y, Jin Y et al. Identification of critical molecular pathways involved in exosome-mediated improvement of cardiac function in a mouse model of muscular dystrophy. Acta pharmacologica Sinica 2020.

121. Cohn RD, van Erp C, Habashi JP et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nature medicine 2007; 13: 204-10.

122. Allen RE, Boxhorn LK. Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. Journal of cellular physiology 1987; 133: 567-72.

123. Li Y, Foster W, Deasy BM et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. The American journal of pathology 2004; 164: 1007-19.

124. Ceco E, McNally EM. Modifying muscular dystrophy through transforming growth factor-beta. The FEBBS journal 2013; 280: 4198-209.

125. Bernasconi P, Torchiana E, Confalonieri P et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. The Journal of clinical investigation 1995; 96: 1137-44.

126. Sun G, Haginoya K, Chiba Y et al. Elevated plasma levels of tissue inhibitors of metalloproteinase-1 and their overexpression in muscle in human and mouse muscular dystrophy. Journal of the neurological sciences 2010; 297: 19-28.
149. Zhao W, Zhao T, Chen Y et al. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Molecular and cellular biochemistry 2008; 317: 43-50.

150. Takenaka H, Kihara Y, Iwanaga Y et al. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. Journal of molecular and cellular cardiology 2006; 41: 989-97.

151. Kakishita M, Nakamura K, Asanuma M et al. Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor. Journal of cardiovascular pharmacology 2003; 42 Suppl 1: S67-70.

152. Lu L, Quinn MT, Sun Y. Oxidative stress in the infarcted heart: role of de novo angiotensin II production. Biochemical and biophysical research communications 2004; 325: 943-51.

153. Zhao QD, Viswanadhapalli S, Williams P et al. NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFkappaB signaling pathways. Circulation 2015; 131: 643-55.

154. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Molecular and cellular endocrinology 2009; 302: 148-58.

155. Somanna NK, Valente AJ, Krenz M et al. The Nox1/4 Dual Inhibitor GKT137831 or Nov4 Knockdown Inhibits Angiotensin-II-Induced Adult Mouse Cardiac Fibroblast Proliferation and Migration. AT1 Physically Associates With Nox4. Journal of cellular physiology 2016; 231: 1130-41.

156. Minas JN, Thorwald MA, Conte D et al. Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats. Clinical and experimental pharmacology & physiology 2015; 42: 1178-88.

157. Cucoranal I, Clempus R, Dikalova A et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circulation research 2005; 97: 1055-64.

158. Colston JT, de la Rosa SD, Strader JR et al. H2O2 activates Nox4 through PLA2-dependent arachidonic acid production in adult cardiac fibroblasts. FEBS letters 2005; 579: 2533-40.

159. Delfin DA, Xu Y, Peterson JM et al. Improvement of cardiac contractile function by peptide-based inhibition of NF-kappaB in the utrophin/ dystrophin-deficient murine model of muscular dystrophy. Journal of translational medicine 2011; 9: 68.

160. Ballmann C, Denney T, Beyers RJ et al. Long-term dietary quercetin enrichment as a cardioprotective countermeasure in mdx mice. Experimental physiology 2017; 102: 635-49.

161. Peng J, Gurantz D, Tran V et al. Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circulation research 2002; 91: 1119-26.

162. Ermolova NV, Martinez L, Vetrone SA et al. Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. Neuromuscular disorders : NMD 2014; 24: 583-95.

163. Mareedu S, Pachon RE, Jayapalraj T et al. Sarcolipin haploinsufficiency prevents dystrophic cardiomyopathy in mdx mice. American journal of physiology Heart and circulatory physiology 2020.

164. Sciorati C, Staszewsky L, Zambrini V et al. Ibuprofen plus isosorbide diminate treatment in the mdx mice ameliorates dystrophic heart structure. Pharmacological research 2013; 73: 35-43.

165. Sriramula S, Francis J. Tumor Necrosis Factor - Alpha Is Essential for Angiotensin II-Induced Ventricular Remodeling: Role for Oxidative Stress. PloS one 2015; 10: e0138372.

166. Farini A, Gowran A, Bella P et al. Fibrosis Rescue Improves Cardiac Function in Dystrophin-Deficient Mice and Duchenne Patient-Specific Cardiomyocytes by Immunoproteasome Modulation. The American journal of pathology 2019; 189: 339-53.

167. Li N, Wang XH, Han QY et al. Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP. Journal of molecular and cellular cardiology 2015; 79: 303-14.

168. Blain A, Greally E, Laval SH et al. Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice. Journal of cardiovascular translational research 2015; 8: 198-207.

169. Lee EM, Kim AY, Lee EJ et al. Therapeutic effects of mouse adipose-derived stem cells and losartan in the skeletal muscle of injured mdx mice. Cell transplantation 2015; 24: 939-53.

170. Meyers TA, Heitzman JA, Krebsbach AM et al. Acute AT1R blockade prevents isoproterenol-induced injury in mdx hearts. Journal of molecular and cellular cardiology 2019; 128: 51-61.

171. Heier CR, Yu Q, Fiorillo AA et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life science alliance 2019; 2.

172. Lowe J, Floyd KT, Rastogi N et al. Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice. Journal of neuromuscular diseases 2016; 3: 395-404.
196. Dystrophin: Raman resonance longitudinal

194. Pioner Jelinkova journal of the American muscle Federation and Bostick muscle

193. Chamberlain and Bostick muscle

192. CTGF/CCN2

191. Cabello Duchenne X, Putten exon -

190. duchenne old

189. years' follow-up. American heart journal 2007; 154: 596-602.

188. Implications for muscular dystrophy: a model for Duchenne muscular dystrophy. Cell 1997; 90: 717-27.

187. Yu X, Bao B, Echigoya Y, Yokota T. Dystrophin-deficient large animal models: translational research and exon skipping. American journal of translational research 2015; 7: 1314-31.

186. Yucel N, Chang AC, Day JW et al. Humanizing the mdx mouse model of DMD: the long and the short of it. NPJ Regenerative medicine 2018; 3: 4.

185. Rovina D, Castiglioni E, Niro F et al. "Betwixt Mine Eye and Heart a League Is Took": The Progress of Induced Pluripotent Stem-Cell-Based Models of Dystrophin-Associated Cardiomyopathy. International journal of molecular sciences 2020; 21.

184. Jelinkova S, Vilotic A, Pribyl J et al. DMD Pluripotent Stem Cell Derived Cardiac Cells Recapitulate in vitro Human Cardiac Pathophysiology. Frontiers in bioengineering and biotechnology 2020; 8: 535.

183. Pioneer JM, Fornaro A, Coppini R et al. Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy. Frontiers in physiology 2020; 11: 368.

182. Bourke JP, Bueser T, Quinlivan R. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. The Cochrane database of systematic reviews 2018; 10: CD009068.

181. Hor KN, Mazur W, Taylor MD et al. Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance 2011; 13: 60.

180. Raman SV, Hor KN, Mazur W et al. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter aIDMD Trial. Journal of the American Heart Association 2019; 8: e013501.

179. Raman SV, Hor KN, Mazur W et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2015; 14: 153-61.

178. Raman SV, Hor KN, Mazur W et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial. Orphanet journal of rare diseases 2017; 12: 39.

177. Duboc D, Meune C, Pierre B et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. American heart journal 2007; 154: 596-602.
197. Jefferies JL, Eidem BW, Belmont JW et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. *Circulation* 2005; 112: 2799-804.

198. Duboc D, Meune C, Lerebours G et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. *Journal of the American College of Cardiology* 2005; 45: 855-7.

199. Ramaciotti C, Heistein LC, Coursey M et al. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life. *The American journal of cardiology* 2006; 98: 825-7.

200. Kajimoto H, Ishigaki K, Okumura K et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. *Circulation journal : official journal of the Japanese Circulation Society* 2006; 70: 991-4.

201. Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. *Journal of cardiology* 2009; 53: 72-8.

202. Kwon HW, Kwon BS, Kim GB et al. The effect of enalapril and carvedilol on left ventricular dysfunction in middle childhood and adolescent patients with muscular dystrophy. *Korean circulation journal* 2012; 42: 184-91.

203. Viollet L, Thrush PT, Flanigan KM et al. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. *The American journal of cardiology* 2012; 110: 98-102.

204. Allen HD, Flanigan KM, Thrush PT et al. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy. *PLoS currents* 2013; 5.

205. Silva MC, Magalhaes TA, Meira ZM et al. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial. *JAMA cardiology* 2017; 2: 190-9.